Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections | Zendy

Martín E. Stryjewski | Zendy; Steven L. Barriere | Zendy; W. O'Riordan | Zendy; Lala M. Dunbar | Zendy; Alan R. Hopkins | Zendy; F. C. Genter | Zendy; G. Ralph Corey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections

Author(s) -

Martín E. Stryjewski,

Steven L. Barriere,

W. O'Riordan,

Lala M. Dunbar,

Alan R. Hopkins,

F. C. Genter,

G. Ralph Corey

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks081

Subject(s) - vancomycin , medicine , staphylococcus aureus , methicillin resistant staphylococcus aureus , staphylococcal skin infections , cellulitis , surgery , skin infection , biology , bacteria , genetics

Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) trials, which demonstrated non-inferiority of telavancin to vancomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research